Pembrolizumab FDA approval date

The FDA approved Pembrolizumab (KEYTRUDA®) on 4 Sep 2014.

FDA approval date
4 Sep 2014

Drug identity checked against registry records

Also recorded as KEYTRUDA®; Keytruda; Keytruda®

Included trials

TrialSponsorPhaseStatusPrimary completion
IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)NCT05155254IO BiotechPhase 3Active not recruiting2025-05-30Actual
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLCNCT06216301NovoCure GmbHPhase 3Recruiting2028-10Estimated
IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal MelanomaNCT05987332IDEAYA BiosciencesPhase 2, Phase 3Active not recruiting2027-01-15Estimated
VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]NCT06264180Replimune, Inc.Phase 3Recruiting2030-09-30Estimated
Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA)NCT07660094CADLPhase 3Recruiting2031-10-22Estimated
A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLCNCT06246110Eikon TherapeuticsPhase 2Active not recruiting2026-12Estimated
Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung CancerNCT03520686IBRXPhase 3Terminated2025-10-13Actual
A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS MutationsNCT04854434KPTIPhase 2Terminated2022-06-24Actual
A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckNCT05271604BioAtla, Inc.Phase 2Completed2025-09-22Actual
Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung CancerNCT04736173RCUSPhase 2Completed2026-09-17Actual
Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal MelanomaNCT03070392Immunocore LtdPhase 2Completed2020-10-13Actual
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid TumorsNCT03645928IOVAPhase 2Terminated2026-02-20Actual
Ordastobart (INBRX-106) Add-on to Pembrolizumab in 1L HPV+ PD-L1+ R/M OPSCC (HexAgon-HN)NCT06295731INBXPhase 2, Phase 3Recruiting2029-12Estimated
Study Assessing Safety and Efficacy of Combination of BL-8040 and Pembrolizumab in Metastatic Pancreatic Cancer PatientsNCT02826486BLRXPhase 2Completed2022-09-06Actual
Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced MelanomaNCT04768881KPTIPhase 2Terminated2023-09-22Actual
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed GlioblastomaNCT06556563NovoCure GmbHPhase 3Active not recruiting2029-04Estimated
Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaNCT06082167ExelixisPhase 2, Phase 3Active not recruiting2028-08Estimated
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract CancerNCT06282575Jazz PharmaceuticalsPhase 3Recruiting2028-12-01Estimated
LUNAR-4: Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Pembrolizumab for Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC)NCT06558799NovoCure GmbHPhase 2Terminated2026-02-23Actual
Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination TreatmentNCT04256707KPTIPhase 1, Phase 2Completed2024-07-31Actual
A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid TumorsNCT07749586ARVNPhase 1, Phase 2Recruiting2031-03-31Estimated
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLCNCT06162221RVMDPhase 1, Phase 2Recruiting2027-06Estimated
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid TumorsNCT07020221VSTMPhase 1, Phase 2Recruiting2028-12Estimated

PDUFA dates and FDA decisions

Date as reportedDrug / companyEventConditionEvidence
2014-09-04DayPembrolizumabFDA original application approvalFDA approval decisionNot specifiedOpen original source
Read source excerpt

{"application_number": "BLA125514", "applicant_as_listed_by_fda": "MERCK SHARP DOHME", "brand_names": ["KEYTRUDA"], "active_ingredients": ["PEMBROLIZUMAB"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20140904", "matched_on": "drug name equals FDA sole active ingredient"}

First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026